Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Alex Shimmings
A number of pivotal studies are expected to report top-line data in the third quarter. Here, with the help of Informa Pharma's Biomedtracker, we take a look at eight of those likely to be major catalysts for their sponsors.
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.
Lacklustre top-line data from the PELICAN study raise concerns over AbbVie's commitment to Galapagos's cystic fibrosis franchise, and leaves rival Vertex even more securely in possession of the field.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The appearance of neutralizing antibodies to Catalyst's investigational subcutaneous Factor IX product sent the company's share price southwards.